Join
Live feed
·
PRReleasevia Quantisnow
Axovant Gene Therapies Ltd. logo

Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 Gangliosidosis

ByQuantisnow·Wall Street's wire, on your screen.
Full content unavailable. See the original source below.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AXGT (Axovant Gene Therapies Ltd.) and more on Quantisnow.